LAG3 and neoplasm: Treatment with this anti-PD-L1 secreting CAR-T cell led to a 50% decrease in T cell exhaustion markers (LAG-3, TIM-3 and PD-1) compared to treatment with a non-secreting CAR-T cell and a three times profounder reduction in tumor mass [92].